Cryo‑Cell International received a NYSE American listing compliance notice on March 9, 2026, citing a stockholders’ deficit as of November 30, 2025 and net losses in two of the last three fiscal years.
The notice references a stockholders’ deficit as of the end of 2025 and highlights net losses of $9.5 million in fiscal 2023, a net income of $402,000 in fiscal 2024, and a net loss of $2.4 million in fiscal 2025, demonstrating a pattern of profitability volatility.
The company must submit a compliance plan by April 8, 2026. If the plan is not accepted or the company fails to regain compliance, NYSE American may initiate delisting proceedings, which would remove the company from public trading and reduce liquidity.
Financial challenges are amplified by significant impairment charges: a $4.4 million impairment in Q4 2025 for inventory and a $13.1 million impairment related to the Duke License Agreement in fiscal 2023, both of which contributed to the net losses and the stockholders’ deficit.
Cryo‑Cell is pursuing capital‑intensive strategic initiatives, including biopharmaceutical manufacturing and clinic operations, which increase cash outflows and strain the company’s balance sheet.
The compliance notice underscores the risk of delisting, which would limit the company’s access to capital markets and could hinder its expansion plans.
The company has indicated it will file a plan to regain compliance, and investors should monitor subsequent filings for updates on its status.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.